×
About 434,353 results

Potandon Produce Voluntarily Recalls Select Red, White, and Yellow Whole Onions Because of Possible Health Risk
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428248

Potandon Produce L.L.C. ofldaho Falls, Idaho is voluntarily recalling Green Giant Fresh whole yellow onions in 2 lb. bags, 3 lb. bags, and 5 lb. bags; whole white onions in 2 lb. bags; and whole red onions in 2 lb. bags delivered directly to three UNFI retail distribution centers (DCs) in Fargo, Nor

Potandon Produce Voluntarily Recalls Select Red, White, and Yellow Whole Onions Because of Possible Health Risk
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428247

Potandon Produce L.L.C. ofldaho Falls, Idaho is voluntarily recalling Green Giant Fresh whole yellow onions in 2 lb. bags, 3 lb. bags, and 5 lb. bags; whole white onions in 2 lb. bags; and whole red onions in 2 lb. bags delivered directly to three UNFI retail distribution centers (DCs) in Fargo, Nor

Benefits of Post-Op Penile Traction Therapy Hold Up Over Time
https://www.medpagetoday.com/urology/prostatecancer/95226

Oct 23rd, 2021 - SCOTTSDALE, Ariz. -- A penile traction therapy (PTT) device produced lasting improvements in men after prostatectomy, a researcher reported. The current data builds on an August 2021 study of 6-month data from 55 men (average age 58.6) who were randomly assigned to control (n=25) or treatment with PTT (n=30) after prostatectomy. The interventions began 1 month post-surgery, and those in the PTT...

Continuous-Release Anti-VEGF Device for AMD Wins FDA Approval
https://www.medpagetoday.com/ophthalmology/generalophthalmology/95225

Oct 23rd, 2021 - The FDA has approved a first-of-its kind continuous delivery system for anti-VEGF therapy for neovascular (wet) age-related macular degeneration (AMD). The Susvimo ocular implant continuously releases 100 mg/mL of ranibizumab directly to the retina over 6 months. Initial implantation and refill can be performed during an office visit with an ophthalmologist. In contrast, conventional intravitre...

Gustavo Fonseca, MD, FACP, Manish Patel, MD, and James Reeves, MD, Co-Author Integrated Safety Analysis of Umbralisib in Lymphoid Malignancies
https://www.onclive.com/view/gustavo-fonseca-md-facp-manish-patel-md-and-james-reeves-md-co-author-integrated-safety-analysis-of-umbralisib-in-lymphoid-malignancies

Oct 22nd, 2021 - Three medical oncologists at Florida Cancer Specialists & Research Institute (FCS) are co-authors on a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies. FCS Director of Clinical Research Gustavo Fonseca, MD, FACP, Director of Drug Development Manish Patel, MD and James Reeves, MD, a member of the FCS clinical research team, participated in the study entitled Int...

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer
https://www.onclive.com/view/agenus-withdraws-bla-for-balstilimab-in-metastatic-cervical-cancer

Oct 22nd, 2021 - The immuno-oncology company Agenus has made the decision to withdraw its biologic license application (BLA) for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.1 The decision follows the full approval of pembrolizumab (Keytruda) on October 13, 2021, for use as a single agent in pat...

Children With Cancer At Higher Risk for Severe Illness from COVID-19
https://www.onclive.com/view/children-with-cancer-at-higher-risk-for-severe-illness-from-covid-19

Oct 22nd, 2021 - Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher in this patient population compared with the general pediatric population, providing evidence that children with cancer are at higher risk of developing severe illness from C...

Oncopeptides Withdraws Melphalan Flufenamide Myeloma Indication in the United States
https://www.onclive.com/view/oncopeptides-withdraws-melphalan-flufenamide-myeloma-indication-in-the-united-states

Oct 22nd, 2021 - Oncopeptides AB (publ) has made the decision to withdraw the indication of melphalan flufenamide (Pepaxto; melflufen) in combination with dexamethasone in select adult patients with relapsed or refractory multiple myeloma from the US market.1 In February 2021, the FDA approved melflufen plus dexamethasone for use in adult patients with relapsed/refractory multiple myeloma who have received at ...

Low androgen in kidney recipients tied to diabetes
https://www.mdedge.com/endocrinology/article/247792/diabetes/low-androgen-kidney-recipients-tied-diabetes
Miriam E. Tucker

Oct 22nd, 2021 - Low androgen levels appear to be linked to the development of posttransplantation diabetes mellitus (PTDM) in male kidney transplant recipients, new research suggests. London_England/Thinkstock Among 243 men who did not have diabetes prior to undergoing kidney transplantation, levels of both dihydrotestosterone (DHT) and testosterone were inversely related to the risk for developing diabetes th.

Exercise may help stall MS disability and progression
https://www.mdedge.com/neurology/article/247787/multiple-sclerosis/exercise-may-help-stall-ms-disability-and-progression
Jim Kling

Oct 22nd, 2021 - Though once regarded with suspicion, exercise as a therapy for multiple sclerosis (MS) has gained traction in recent years, and has the potential to counter the physical effects often seen among patients, as well as reduce risk of progression. Dr.

Explainer-Americans wonder: Which COVID-19 booster is best?
https://www.reuters.com/article/us-health-coronavirus-boosters-explainer/explainer-americans-wonder-which-covid-19-booster-is-best-idUSKBN2HC243

Oct 22nd, 2021 - CHICAGO (Reuters) - Americans this week were handed a big decision when it comes to getting a COVID-19 vaccine booster. The U.S. Centers for Disease Control and Prevention (CDC) on Thursday said individuals who qualify could choose a different vaccine from the one they received for their initial inoculation. For Americans asking how to choose, the following is what some experts advise: The CDC ...

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC
https://www.onclive.com/view/tas-102-plus-bevacizumab-misses-pfs-end-point-in-frontline-unresectable-metastatic-crc

Oct 22nd, 2021 - The frontline combination of trifluridine/tipiracil (TAS-102; Lonsurf) and bevacizumab (Avastin) was not found to result in a significant improvement in progression-free survival (PFS) over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer (mCRC) who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial (...

COVID Vaccine Recipients Also Less Likely to Die of Other Causes
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/95220

Oct 22nd, 2021 - People who were vaccinated against COVID-19 were also less likely to die from non-COVID-19-related causes compared with unvaccinated people, researchers found. The adjusted relative risk of non-COVID-19 mortality ranged from 0.31 (95% CI 0.30-0.33) for those who received two doses of Moderna to 0.54 (95% CI 0.49-0.59) for Johnson & Johnson recipients, reported Stanley Xu, PhD, of Kaiser Permane...

Walmart, Walgreens U.S. stores roll out Moderna, J&J COVID-19 booster shots
https://www.reuters.com/article/health-coronavirus-boosters/update-4-walmart-walgreens-u-s-stores-roll-out-moderna-jj-covid-19-booster-shots-idUSL4N2RI3BC

Oct 22nd, 2021 - (Reuters) -Walgreens Boots Alliance Inc and Walmart Inc said on Friday their U.S. pharmacies started administering COVID-19 booster shots from Moderna Inc and Johnson & Johnson, in addition to previously authorized Pfizer-BioNTech booster. The Centers for Disease Control and Prevention (CDC) on Thursday recommended J&J and Moderna’s booster shots and said Americans can choose a different shot f...

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC
https://www.onclive.com/view/pembrolizumab-chemo-approved-in-europe-for-select-locally-recurrent-unresectable-or-metastatic-tnbc

Oct 22nd, 2021 - The European Commission has approved pembrolizumab (Keytruda) plus chemotherapy for the frontline treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors have a PD-L1 expression combined positive score (CPS) of 10 or higher and who have not previously received chemotherapy for metastatic disease.1 The regulatory decision is ba...

Burnout a Risk Factor for Suicidal Thoughts in Nurses
https://www.medpagetoday.com/nursing/nursing/95217

Oct 22nd, 2021 - Nurses experiencing burnout were twice as likely to have thoughts of suicide, and those with symptoms of depression were 11 times as likely to experience suicidal thoughts, a survey study found. Among more than 7,000 nurses surveyed from November to December 2017, a total of 5.5% experienced suicidal ideation, which is higher than rates of suicidal thoughts in the general population (4.3%), rep...

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing
https://www.onclive.com/view/a-wealth-of-therapeutic-advances-in-lung-cancer-stress-a-need-for-early-ngs-testing

Oct 22nd, 2021 - The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care, said Stephen V. Liu, MD. Our strategies [for managing lung cancer] are becoming more sophisticated and precise, but the first step of broad next-generation sequencing [NGS] is really the key. NGS is essential t...

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC
https://www.onclive.com/view/fda-approves-companion-diagnostic-for-adjuvant-atezolizumab-in-stage-ii-to-iiia-nsclc

Oct 22nd, 2021 - The FDA has approved the VENTANA PD-L1 (SP263) assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab (Tecentriq) following surgery and platinum-based chemotherapy.1 Adjuvant atezolizumab was approved for use in this indication on O...

Too Many TAVR Centers Are Clustered Around Well-to-Do Communities
https://www.medpagetoday.com/cardiology/pci/95213

Oct 22nd, 2021 - The proliferation of transcatheter aortic valve replacement (TAVR) programs in the U.S. was largely limited to metropolitan areas and hospitals serving relatively affluent patients, a study found. Only 2% of the 583 hospitals with a TAVR program by the end of 2018 were not located in metropolitan areas, and there was only one rural center. Furthermore, half of new programs established in 2012 t...

Washington subway to continue reduced service through at least Oct. 31
https://www.reuters.com/article/usa-washington-subway/washington-subway-to-continue-reduced-service-through-at-least-oct-31-idUSL1N2RI1DP

Oct 22nd, 2021 - WASHINGTON, Oct 22 (Reuters) - The Washington-area subway system said Friday it will continue sharply reduced subway service through at least Oct. 31 as it works to finalize plans to return most of its railcars to service after an Oct. 12 derailment. The Washington Metropolitan Area Transit Authority (WMATA) on Sunday was ordered to indefinitely remove about 60% of the subway system’s railcars ...